NAN is in the benchmark, a pathology sterilisation company.
The market was looking for >$92m of sales in the 1H, and an NPAT of ~$7m.
So quite a large downgrade to consensus, based on the trading update released overnight.
We watch NAN because it is in the benchmark, and because it’s been fascinating to see such a dramatic valuation attached to the business model.
Like many of its medtech brethren, NAN has traded well over 10x revenues, for much of the past few years. Even if one disagreed with the idea of 10x revenues as being a bit rich, one can at least agree to lump it into the “concept stock” camp, whereby if it executes, the sky is the limit on sales, but if it doesn’t, the basement.
We’ve been of the view that NAN’s c40% share of the US market, whilst impressive, still only translated to a mildly profitable business at the group level, which makes it hard to justify the overall market cap, and implies similarly perfect execution everywhere else, which is simply hard to do.
In any case, the old “aftermarket” trading update will be met poorly at market open.
Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.
This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.
Please note that past performance is not a reliable indicator of future performance.
General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.
Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.